- Conditions
- Hypersomnia, Primary Hypersomnia, Idiopathic Hypersomnia, Narcolepsy Without Cataplexy
- Interventions
- Flumazenil
- Drug
- Lead sponsor
- Lynn Marie Trotti
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
- Interventions
- AXS-12 (Reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
- Interventions
- AXS-12 (reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 47
- States / cities
- Alabaster, Alabama • Peoria, Arizona • Phoenix, Arizona + 43 more
- Conditions
- Narcolepsy, Excessive Daytime Sleepiness, Cataplexy Narcolepsy
- Interventions
- mazindol extended release, Placebo
- Drug
- Lead sponsor
- NLS Pharmaceutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Redwood City, California • San Diego, California + 17 more
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Somnolence, Sleep Disorder, Sleep Disturbance, Sleep Wake Disorders
- Interventions
- FT218
- Drug
- Lead sponsor
- Avadel
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Redwood City, California • Santa Ana, California + 24 more
- Conditions
- Narcolepsy Without Cataplexy, Idiopathic Hypersomnia, Narcolepsy With Cataplexy
- Interventions
- Clarithromycin, Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
- Interventions
- AXS-12 (reboxetine), Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 15 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
- Conditions
- Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2)
- Interventions
- TAK-994, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 36
- States / cities
- Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 31 more
- Conditions
- Narcolepsy Type 1 (NT 1)
- Interventions
- TAK-994, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 35
- States / cities
- Alabaster, Alabama • Phoenix, Arizona • Bellflower, California + 29 more
- Conditions
- Narcolepsy Type 1
- Interventions
- ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 22
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- Narcolepsy, Narcolepsy Type 1, Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy, Nightmare, Nightmare Disorder With Associated Other Sleep Disorder
- Interventions
- Imagery Rehearsal Therapy (IRT)
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Narcolepsy, Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
- Interventions
- Brief MBI, Standard MBI, Extended MBI
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
- Interventions
- TAK-861, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 11
- States / cities
- Redwood City, California • Brandon, Florida • Miami, Florida + 8 more
- Conditions
- Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
- Interventions
- Pitolisant
- Drug
- Lead sponsor
- Harmony Biosciences Management, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more
- Conditions
- Narcolepsy Type 2
- Interventions
- Placebo, TAK-861 2 mg, TAK-861 2 mg and 5 mg
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Redwood City, California + 18 more
- Conditions
- Narcolepsy
- Interventions
- SUVN-G3031, Placebo
- Drug
- Lead sponsor
- Suven Life Sciences Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more
- Conditions
- Narcolepsy Type 1
- Interventions
- TAK-360, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 3
- States / cities
- Redwood City, California • Miami, Florida • Cincinnati, Ohio
- Conditions
- Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
- Interventions
- CEP-10953 (Armodafinil)
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 41
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more
- Conditions
- EDS, Cataplexy, Fatigue, Narcolepsy
- Interventions
- HBS-301, Placebo
- Drug · Other
- Lead sponsor
- Harmony Biosciences Management, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 46 more
- Conditions
- Narcolepsy
- Interventions
- SEP363856, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Orange, California • St. Petersburg, Florida • Atlanta, Georgia + 3 more
- Conditions
- Narcolepsy Type 1
- Interventions
- TAK-861, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Redwood City, California • Santa Ana, California + 18 more
- Conditions
- Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
- Interventions
- FT218, Placebo
- Drug
- Lead sponsor
- Avadel
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 38
- States / cities
- Anniston, Alabama • Auburn, Alabama • Birmingham, Alabama + 32 more
- Conditions
- Narcolepsy With or Without Cataplexy
- Interventions
- APD916
- Drug
- Lead sponsor
- Arena Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Narcolepsy Type 1
- Interventions
- Oveporexton, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Redwood City, California • Santa Ana, California + 12 more